Seer (SEER) Proxy filing summary

Executive summary

• Annual meeting scheduled for July 28, 2026, with a focus on electing directors to guide long-term growth and innovation.

• Board urges shareholders to vote for its slate of seven highly qualified nominees to protect investment value.

• Emphasis on operational discipline, product innovation, and prudent capital allocation to drive commercial adoption.

• Board collectively owns 17% of outstanding shares, demonstrating alignment with shareholder interests.

Voting matters and shareholder proposals

• Shareholders are asked to vote for the Board's director nominees using the BLUE proxy card.

• Competing nominees, supported by Bradley Radoff and Michael Torok, are criticized for lacking relevant experience.

• Board warns that electing the opposing nominees could disrupt momentum and risk shareholder value.

Board of directors and corporate governance

• Seven director nominees have deep industry expertise in life sciences and proteomics.

• Board described as highly engaged, independent, and purpose-built for the company's strategic needs.

• Board members include Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Dipchand Nishar, Isaac Ro, and Nicolas Roelofs.